We happily present new additions to the LinXis scientific portfolio
To create our Fibrobody-drug conjugates, we use our unique Lx linker technology in a process that entails two key steps. First, the drug is coupled to the Lx linker to produce a highly stable and storeable intermediate in a fully scalable process. We described this process earlier this year in the high-impact journal Green Chemistry. In the second step, this drug-linker complex is conjugated to the desired fibrobody or antibody in a highly efficient, easily scalable, and general bio-conjugation process. In our recent work, which was recently accepted for publication in the renowned journal Angewandte Chemie, LinXis' Head of Chemistry dr. Eugen Merkul reveals the optimization of our conjugation process, accompanied by novel chemistry and a multigram scale synthesis of a lead conjugate, whose favorable properties were confirmed in in-vitro and in-vivo studies.
We believe that image-guided drug design is crucial to succesful development of targeted therapeutics. For this reason we are extremely happy to be based in the Amsterdam Imaging Center, and to have Guus van Dongen on board as our new CSO. In his recent paper in the Journal of Nuclear Medicine, titled “The navigating and de-risking role of 89Zr-immuno-PET in the development of biopharmaceuticals”, Guus and colleagues of the Amsterdam University Medical Center review the power of PET imaging for efficient development of biopharmaceuticals. Not only does PET imaging allow visualization and quantification of the drug in the living body - effectively privoding visual proof that the drug effectively travels to the target organ, it may even be used to accurately monitor whether the drug is curing the disease - without requiring a single drop of blood.
These publications underline our vision and strategy in the development of effective Fibrobody-drug conjugates for the treatment of fibrotic disease.
Share this article